Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1FED 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

CNS 4Gastrointestinal 3Head & Neck 2Breast 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Brain Neoplasms 1905Glioblastoma 1797Glioma 1130Central Nervous System Neoplasms 599Astrocytoma 594Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 364Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 227Recurrence 199Sarcoma 184Neoplasm Metastasis 183Melanoma 182Meningioma 177Ependymoma 176Lung Neoplasms 157Lymphoma 134Osteosarcoma 127Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 101Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

XENP 1595 2Dialectical Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Mental Disorders × CNS × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

NCT05393492 2022-05-26

GREMO-LCA

University Hospital, Strasbourg, France

Phase NA Unknown
77 enrolled
CNS

Mental Disorders, Brain Injuries, Brain Neoplasms, Hypoxia, Brain, Encephalitis, Ischemia, Meningitis, Stroke

NCT00004437 2015-03-25

Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2

FDA Office of Orphan Products Development

Phase 2 Completed
CNS

Mental Disorders, Neurologic Manifestations, Neuroma, Acoustic, Neurofibromatosis 2, Neurofibromatoses, Genetic Diseases, Inborn, Hearing Loss, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡